Axon Enterprise, Inc. (NASDAQ:AXON) Receives $488.67 Average Price Target from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has received a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $488.67.

A number of brokerages recently issued reports on AXON. Northland Securities raised their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Robert W. Baird lifted their price objective on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. The Goldman Sachs Group upped their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. JMP Securities raised their price target on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st. Finally, Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total value of $12,123,000.00. Following the completion of the transaction, the president now owns 208,166 shares in the company, valued at $126,179,820.90. This represents a 8.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 3.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,545 shares of company stock valued at $31,159,317 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXON. Quent Capital LLC lifted its holdings in Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares in the last quarter. Prestige Wealth Management Group LLC increased its position in shares of Axon Enterprise by 115.8% during the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 44 shares during the last quarter. Brooklyn Investment Group acquired a new position in shares of Axon Enterprise in the third quarter worth about $41,000. Asset Dedication LLC purchased a new position in Axon Enterprise in the second quarter valued at about $47,000. Finally, Planning Capital Management Corp increased its holdings in Axon Enterprise by 83.3% during the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 55 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $596.49 on Tuesday. The company has a 50-day simple moving average of $590.55 and a 200-day simple moving average of $437.04. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company has a market cap of $45.49 billion, a PE ratio of 154.13, a price-to-earnings-growth ratio of 14.19 and a beta of 1.01. Axon Enterprise has a 12 month low of $241.72 and a 12 month high of $698.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.